Background: malignant pleural mesothelioma (MPM) represents a common malignant disease. It is an aggressive tumor arising from the mesothelial cells lining the pleura. There is an extremely poor prognosis and a vast majority of MPM patients are diagnosed in an advanced stage. Rapid progression of the disease, no effective therapeutic approach and resistance to chemotherapy and radiotherapy resulted in a median survival time of less than 12 months. Aim of the Work: this study aimed to analyze the clinic pathological profile, the various prognostic factors and treatment response of malignant mesothelioma patients in our center in terms of overall survival and progression free survival. Patients and Methods: this retrospective was conducted on Malignant Mesothelioma patients who presented to the Department of Clinical Oncology, Ain Shams University from 1 January, 2011 to 31 December, 2014. Results: the mean age of the included patients were 61.04 years with male predominance 50.6% and female 49.1%. Occupational risk was documented in only 11.1% of included patients; most patients live in the industrial environment (67.9%) and the rest in non industrial environment (32.1%). All patients had negative family history of cancer. All patients had negative surgical history, 66.7% of patients had positive history of asbestos exposure. The commonest co morbidity among the studied patients were HTN as it was accounted for 24.7% of the included patients followed by diabetes mellitus in 16% of patients on the other hand, only 3.7% of patients had no co morbidity. Dyspnea was the commonest symptoms (77.8%) among the included patients, followed by cough (33.3%) and chest pain in 12.3%, the other symptoms with lower presentation included hemoptysis and anemia. P.S 1(28.4%) was recorded among the included patients and 53.1% patients had P.S 2 while, rest of patients 18.5% had P.S 3. Patients were diagnosed by CT chest and pleural biopsy either US guided or CT guided, chest X ray, thoracoscopic biopsy, FNAC and open pleural biopsy. The results also showed that the median PFS among the included patients was 2 months. Median OAS was 6.1 months. Conclusion: best survival data in patients with MPM were currently reported from groups using multimodality treatment including MCR achieved either by EPP or extrapleural decortication for patients qualifying as far as tumor stage and functional reserve were concerned. In general, several treatment combinations have been applied ranging from systemic (neo-or adjuvant) to localized chemotherapy, neo-or adjuvant radiotherapy and others. Recommendations: The choice of the surgical procedure should be tailored according to tumor stage, performance status, and institutional experience. Morbidity and mortality of these treatment approaches have been reduced at experienced centers indicating that this complex treatment should be performed at dedicated high volume mesothelioma centers.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is considered to be a relatively rare tumor. In Great Britain, the incidence in males was 3.4/100 000, in France it was 2.3/100 000 and in the Netherlands it was 3.2/100 000 (1) . In Egypt, epidemiological data on MPM incidence was not available since there was no comprehensive national population-based cancer registry. However, official statistics, as well as Egyptian National Cancer Institute (NCI) and Hospital based registries, showed that MPM incidence in Egypt was rising markedly. The NCI hospital-based registry showed an increase in the relative frequency of MPM from 0.47% in 2001 to 1.3% in 2003 (2) .In Egypt, according to NCI; Cairo University cancer registries pleural malignancy constituted 1.4% ranking 16 th (3)
. A study performed in Clinical Oncology Department, Ain Shams University showed that 304 patients were referred to the clinic between January 2003 and December 2008, for further management after being diagnosed with MPM. One hundred and ninety patients (62.5%) came from endemic areas (Shoubra El Kheima, Helwan, and El Hawamdia) and/or had a history of occupational asbestos exposure; the majority (101 patients) came from Shoubra El Kheima. One hundred and fifty-six patients (51.3%) had a history of smoking and the majority (128 patients) were men 156 more than 80% of the cases makes MPM a preventable disease. Although the Western world is moving towards a levelling-off of ARD (Asbestos related disease) incidence, the continued use of asbestos in the developing world may lead to a global epidemic of MPM (5) .The latency period of MM, i.e., the time elapsed from exposure to the offending agent (in particular, the aforementioned mineral fibers) to diagnosis is long; however, the time elapsed from the onset of malignancy to diagnosis is indeed short, MM producing symptoms shortly after its initial growth (6) .A germ line mutation in the BAP1 gene has been linked to predisposition in some cases of MPM, Somatic mutations may also play a role in the development of MPM (5) . Patients with suspected malignant mesotheliomoa often have dyspnea and chest pain, they can also have pelural effusion,fatigue, insomnia, cough, chest wall mass, loss of appetite and loss of weight (6) .
The recommended initial evaluation for suspected MPM includes: 1) CT of the chest with contrast, 2) Thoracentesis for cytologic assessment and 3) Pleural biopsy (eg, thoracoscopic biopsy [preferred] .
However, cytologic samples are often negative even when patients have MPM
(7)
. Calretinin, WT-1, D2-40 and cytokeratin (CK) 5/6 are useful markers for the diagnosis of MPM, as markers that are typically positive in mesothlioma (8) . The histologic subtypes of mesothelioma include epithelioid (most common), biphasic or mixed and sarcomatoid. Patients with epithelioid histology have better outcomes than those with either mixed (biphasic) or sarcomatoid histologies (8) . The clinical factors relevant to management of MPM included basic epidemiologic variables, clinical condition, common blood assays, imaging assessment and gross tumor features, as well as the anatomic extent of the disease, many of these variables have been combined into prognostic categories to reinforce their predictive power (9) . As regard to the treatment of MPM, trimodality therapy using chemotherapy, surgery and hemithoracic RT has been used in patients with MPM. Median survival up to 29 months has been reported for patients who complete trimodality therapy. Nodal status and response to chemotherapy can affect survival in a small retrospective series; trimodality therapy using extrapelural pneumonectomy (EPP) did not improve survival when compared to patients who did not receive EPP (10) . Surgery is used for staging procedures or with palliative or curative intent.
Using VATS or thoracoscopy, large biopsy samples can be obtained for proper pathological, molecular and IHC analyses. During this procedure, the local extent of the tumor can be examined. Pleural effusions can be drained and, if required, a decortication or pleurodesis can be carried out (11) . Radiotherapy (RT) can be used for different indications in mesothelioma as palliation (12) , as preventive treatment and as part of a multimodality treatment (13) . A combined first-line regimen using cisplatin and pemetrexed (category 1) is considered the gold standard for MPM and is currently the only regimen approved by the U.S. Food and Drug Administration for MPM (14) . A phase III randomized trial assessed cisplatin/pemetrexed versus cisplatin alone in patients who were not candidates for surgery; the combined regimen increased survival when compared with cisplatin alone (12.1 vs. 9.3 months, P=.02) (15) . Other acceptable first-line combination chemotherapy options recommended by NCCN include: 1) Pemetrexed and carboplatin, which was assessed in 3 large phase II studies (median survival = 12.7, 14 and 14 months, respectively) (16) . A comparison of 1,704 patients with medically inoperable MPM treated with cisplatin/ pemetrexed or carboplatin/pemetrexed as part of an expanded access trial found that outcomes with the regimens were similar. The carboplatin/pemetrexed regimen is a better choice for patients with poor PS and/or comorbidities. Acceptable first-line single-agent options include pemetrexed or vinorelbine (17) . 2) Gemcitabine and cisplatin, which were also assessed in phase II studies (median survival = 9.6 to 11.2 months).
Gemcitabine and cisplatin may be useful for patients who cannot take pemetrexed (18) . Second-line chemotherapy options include, pemetrexed (if not administered first line) (category 1), vinorelbine, or gemcitabine (19) . Data suggested that rechallenging with pemetrexed was effective if patients had a good response to firstline pemetrexed (20) . Limited data are available to guide second-line therapy, although several agents are in clinical trials (21) . With all currently available therapies, response rates remain low and the goal of treatment must be optimal palliation. Two major symptoms, dyspnea and chest wall pain, remain the focus of palliative efforts in patients with advanced malignant mesothelioma. Because of the poor aeration of the lung, fatigue becomes debilitating with little help from supplemental oxygen (22) . Evidence of the palliative benefit of chemotherapy was available for vinorelbine, pemetrexed/cisplatin and the combination of mitomycin, vinblastine and cisplatin (15) . .
AIM OF THE WORK
This study aimed to retrospectively analyze the clinic pathological profile, the various prognostic factors and treatment response of malignant mesothelioma patients in our center in terms of overall survival and progression free survival.
PATIENTS AND METHODS
This The tolerability of chemotherapy was evaluated before each cycle of chemotherapy Hematologic assessment performed before each cycle. &Toxicity. Clinical examination was performed every 3 months in the first 2 years and every 6 months there after. Radiological assessment included CT chest and pelviabdominal every 3 cycles of chemotherapy. After completion of chemotherapy all patients have been subjected to follow up with CT chest & pelviabdomen and the chest and pelviabdominal CT with contrast every 6 months in the first 2 years and every 1 year thereafter.
The time and the site(s) of relapse (local, regional or distant) of each patient were recorded. The patients who developed treatment failure either local or distant have been evaluated clinical, radiological (CT) and histopathological "when indicated" to determine site and extent of treatment failure.
-Response
A complete response (CR) was defined as the complete disappearance of all disease with no new lesions. A partial response (PR) was defined as 50% or more reduction from baseline of the sum of the products of the perpendicular diameters of target lesions when only bidimensionally measurable disease was present, or as 30% or more decrease in the sum of the greatest diameters of target lesions when only un-idimensionally measurable lesions were present.
When both types of diseases were present, PR was defined as a reduction of either type of disease as defined above, with the other type at least stable, with non-measurable lesions being at least stable, and no new lesions.
Tumor progressive disease (PD) was defined as the appearance of new or relapsed lesions, a 50% or higher increase in the sum of products of all bidimensionally measurable lesions over the smallest sum observed when only bidimensional disease was present, or a 25% or higher increase in the sum of the longest dimension of unidimensionally measurable lesions over smallest sum observed when only unidimensional disease was present (15) . Toxicity to treatment: was assessed after each cycle of chemotherapy to evaluate the treatment tolerability.
Disease free Survival and Progression free survival:
Disease free survival (DFS) was calculated from the date of diagnosis to the date of disease recurrence and or distant metastasis and Overall survival (OS) from the date of diagnosis to the date of death or the date of last follow up. The median duration of DFS and OS were calculated using the Kaplan-Meier method. The study was approved by the Ethics Board of Ain Shams University.
Data collection and Analysis
The collected data were revised, coded, tabulated and introduced to a PC using Statistical package for Social Science (SPSS 15.0 for windows; SPSS Inc, Chicago, IL, 2001.
Data were presented and suitable analysis was done according to the type of data obtained for each parameter.
Descriptive statistics
Mean, standard deviation (± SD), minimum and maximum values (range) for numerical data, frequency and percentage of non-numerical data.
Analytical statistics
The Independent-Samples T Test was used to assess the statistical significance of the difference between the study groups means. Chi-Square test was used to examine the relationship between two qualitative variables.
RESULTS
This retrospective study was conducted on 81 patients with pathologicaly proven malignant mesothelioma, who presented to the Clinical Oncology Department of Ain shams University Hospital from 1Jan. 2011 to 31Dec. 2014. Clinicopathologic and demographic criteria of the studied population Occupational risk was documented in only 11.1% of included patients, most patients live in the industrial environment (67.9%) and the rest in non industrial environment (32.1%). All patients had negative family history of cancer.
All patients had negative surgical history, 66.7% of patients had positive history of asbestos exposure. The commonest comorbidity among studied patients were HTN as it accounted for 24.7% of the included patients followed by diabetes mellitus in 16% of patients on the other hand only 3.7% of patients had no co morbidity.
Dyspnea was the commonest symptom (77.8%) among the included patients, followed by cough 33.3% and chest pain in 12.3%, the other symptoms with lower presentation includes hemoptysis and anemia. P.S 1(28.4%) was recorded among the included patients and 53.1% patients had P.S 2, while rest of patients 18.5% had P.S 3. Patients were diagnosed by CT chest and pleural biopsy either US guided or CT guided, chest X-ray, thoracoscopic biopsy, FNAC and open pleural biopsy. 4.14 ± 1.56 This table showed that the most common chemotherapy used as second line among included 14 patients was navelbine in 50% followed by alemta\cis 3 rd in 35.7% with mean number of cycles 4.14. (24) found that malignant pleural mesothelioma (MPM) is a relatively rare and highly lethal tumor induced by asbestos exposure, with a growing incidence over the last decades. As it has a highly aggressive behavior; there have been some studies to identify more accurate prognostic factors and staging systems and to investigate novel treatment regimens. However, the relative rarity of this neoplasm has limited research opportunities, and only a few clinical trials have been done or are on-going. Billé et al. (25) found that chemotherapy alone for advanced stages, or in combination with surgery and/or radiotherapy for resectable disease, is the mainstay of treatment. For many patients with locally advanced disease that is not surgically resectable because of tumor invading the chest wall or the mediastinal structures, treatment options are limited to palliative chemotherapy, radiotherapy or best supportive care alone .The same authors found that various prognostic factors for survival in MPM have been described. The most significant prognostic factor remains the histology; epithelioid mesothelioma is the subtype with the best prognosis. The tumor, node and metastasis staging system has been validated in several large series, but the radiological assessment of tumor extension is limited and can underestimate the real extent of the tumor.
In the present study, we retrospectively analyzed the clinic pathological criteria, the various prognostic factors and treatment response of malignant mesothelioma patients presented from 1 Jan 2011 to 31 Dec 2014 at the Department of Clinical Oncology, Ain Shams Hospital in terms of overall survival and progression free survival,81 patients were included. We found that the mean age of the included patients was 61.04 years with male predominance 50.6% and female 49.4%. Occupational risk was documented in only 11.1% of included patients, most of the patients (67.9%) lives in the industrial environment, in Shobra, Helwan. Kalyobia and Elsowais and the rest in non industrial environment (32.1%).
All patients had negative family history of cancer and had negative surgical history. Positive family history of asbestos exposure was recorded in 66.7% of patients. the commonest co morbidity among the studied patients were HTN as it accounted for 24.7% of the included patients followed by diabetes mellitus IN( 16%) of patients. On the other hand, only 3.7% of patients had no co morbidity as regarding to performance status ( 28.4%) of included patients had P.S 1 and 53.1% had P.S 2 the rest of patients (18.5%) had P.S 3.
Similarly, Labby et al. (26) found that of the 78 MPM patients included in this study, 66 were men and 12 were women. The median patient age at study entry was 66 years (range, 41-80 years).
While, Akl et al. (27) demonstrated after full analyzing demographic data of the 165 patient study population and they showed that the mean age cases was 50.78 ±13.5 years, ranging from 15 to 83 years, 94 were males (57%) and 71 were females (43%), male/female ratio was 1.3/1. These results are similar to study done by Billé et al. (25) as they concluded that among the 413 patients with MPM who were treated between January 2000 and December 2013 that the patient's median age was 71 years and 147 (77%) were men.
In addition, Ceresoli et al. (28) in their study they found that among the 715 MPM cases diagnosed at the six participating Hospitals in the study period median age was 75 years, with a range from 70 to 92. Forty-eight cases (20%) were 80 years or older. Patients were mainly males (64%), with ECOG-PS of 0-1 (94%). This is supported by the findings of Adel et al. (4) who showed that out of the 165 cases, 45 (27.3%) cases were reported from Helwan, followed by 34 (20.6%) cases from Shobra and in the neighbouring areas of both, 25 (15.2%) cases in Giza, and 11 (6.7%) cases in Kaliobeya. From Upper Egypt 21 (12.7%) cases were reported and 29 (17.5%) cases were from other parts of Egypt including Alexandria, Alesmaeleia, Alseweis, Algharbeia, Alsharqeia and areas in Cairo other than Helwan and Shobra. This is in coincidence with results of Akl et al. (27) who found that occupational risk factors account for only 23 (13.9%) patients as they were working in asbestos industries, while 142 (86.1%) patients were not exposed to this hazard during working hours.
As regarding major comorbiditied Ceresoli et al. (28) found that no major co morbidity was found in 145 patients (60%), whereas at least one comorbid condition was reported in 92 (38%). Main reported co morbidities were peripheral vascular disease, diabetes and chronic liver disease.
However, Karabulut et al. (24) in their retrospective study on 53 patients with MPM they found that the performance status on admission was ECOG 0 in four patients (7.5%), ECOG 1 in 44 patients (83%) and ECOG 2 in five patients (9.4%).
In the present study we found that dyspnea was the commonest symptoms among the included patients (77.8%) followed by cough (33.3%) patients and chest pain in 12.3% patients the other symptoms with lower presentation included hemoptysis and anemia. This is partially in agreement with results of Brims et al. (29) , they showed that 80.9% of patients presented with dyspnea, 58.5% presented with chest pain and 47.5% presented with weight loss.
In the present study the cases were diagnosed with CT chest, pleural biobsy either ultrasound guided or CT guided also thoracoscopic biopsy used for diagnosis and FNAC from effusion. Chest X-ray was the initial tool of diagnosis in almost all the cases. This is matched with the study of Akl et al. (27) who found that thoracoscopy was done in 70 (42.4%)cases, open pleural biopsy in 56 (33.9%) cases, fine needle aspiration cytology (FNAC) in 10.3% (17 cases), CT-guided biopsy in 9.1% (15 cases), a single case was diagnosed by thoracocentesis (0.6%) .
In the present study as regarding pathological type 82.7% of patients had epithelial type mesothelioma,12.3% had sarcomatoid type and (5%) had biphasic.
These results coincide with the study done by Genestreti et al. (30) where the histologic examination revealed an epitheliod subtype in 7 (88%) cases and a mixed subtype in 1 (12%).
In addition Akl et al. (27) found that epithelioid mesothelioma represents the most common histopathological subtype of MPM diagnosed in 114 (69.1%) cases, followed by biphasic subtype in 43 (26.1%) and sarcomatoid type in 8 (4.8%) cases. No case was diagnosed as desmoplastic.
Ceresoli et al. (28) found that more than two thirds of patients had an epithelioid histological subtype.
In addition, Karabulut et al. (24) found that histological subtypes, 35 patients (66%) were epithelial, 3 patients (5.7%) were sarcomatous, 7 patients (13.2%) were mixed type and 8 patients (15.1%) had undefined pathology.
In the present study regarding TNM staging, stage II was the commonest stage in the included patients( 44.44%) followed by stage III in 24.7% ,IV in 18.5%,Ib in 11.1% and I in 1.2%.
However, Genestreti et al. (30) found that 7 patients (88%) had stage I and 1 (12%) had stage II diseases. This is partially in agreement with results of Ceresoli et al. (28) who reported stage I&II in 149 patients (62%), while stage III-IV in 92 (38%) patients.
While, Karabulut et al. (24) found that in terms of stages, 17 patients (32.1%) were stage 1,18 (34%) patients were stage 2, 7 (13.2%) patients were stage 3 and 11 (20.8%) were stage 4
Moreover Liu et al. (31) found that thirteen patients with low radiologic TNM stage (stage I, n= 3; stage II, n =10) ; whereas seventeen patients with high radiologic TNM stage (stage III, n = 12; stage IV, n = 5)
On the other hand, another study done by Labby et al. (26) showed that CT staging identified 11 patients as stage I, 3 patients as stage II, 34 patients as stage III, and 30 patients as stage IV.
In the present study, we found that 58% of patients had no surgical interference due to advanced disease and 40.7% had palliative surgical interference either before or after receiving chemotherapy with or without radiotherapy, but only 1.2% patients had curative debulking surgical interference. The surgical interference included extrapleural pneumonectomy in 2 patients,decortication in 6 patients, palliative insertion of intercostal chest tube in 17 patients and pleurodysis in 8 patients.
Akl et al. (27) showed that surgery was performed in 58 cases either alone or combined with chemotherapy, extrapleural pneumonectomy in 49 cases, out of which in addition pericardiectomy was performed in 3 cases and excision of extrathoracic swelling in another 3 cases. Pleurectomy was the choice in 8 cases and metastasectomy in a single case.
While, Adel et al. (4) showed that seven patients (2.3%) underwent surgery in the form of extrapleural pneumonectomy or pleurectomy/decortication and were excluded from this analysis due to incomplete data. Those patients did not receive neo-or adjuvant chemotherapy and did not return for follow up. This is partially in agreement with results of Billé et al. (25) who found that at the time of surgery, all 52 patients were found to have unresectable disease due to chest wall involvement (n= 47) patients or mediastinal invasion (n= 5) patients.
However Karabulut et al., (24) study, they found that a total of 19 patients were referred to the clinic after surgery. Twenty-six patients combined treatment with radiotherapy plus Dalia El-Khodary et al. 167 chemotherapy and trimodality were performed in 12 patients, respectively.
Regarding radiotherapy, the present study showed that 74.1% of patients had no radiotherapy on the other hand 2.5% had adjuvant radiotherapy and 23.5% had palliative radiotherapy either to areas of bony metastasis or to the site of biopsy.
In Adel et al. (4) study they recorded that palliative radiotherapy was given to 42 patients (13.8%), either as hemithoracic irradiation or localized radiotherapy to the biopsy site
In the present study, as regard chemotherapy given the most common used chemotherapy regimens among included patients was Gem\Cis in( 66.7%) of patients with mean number of cycles was 4.43 and the most common chemotherapy used as second line among 14 patients was navelbine in 50% followed by alemta\cis as 3 rd in 35.7% , 5 patients with mean number of cycles 4.14. While, 60 % of patients had received alemta\carb and alemta/cis as 3 rd line and alemta alone in 20% with mean number of cycles 5.80. in the present study patients received chemotherapy either as a monomdality therapy in 33,3% or as a part of multimodality therapy combined with surgery and radiotherapy in 9,9%. 18.5% of patients had only best supportive care due to bad performance and old age. This is in accordance with the study done by Adel et al. (4) who showed that one hundred and sixty-nine patients (55.6%) received chemotherapy. The majority of patients (150 patients, 91.7%) received platinum-based chemotherapeutic regimens (etoposide/cisplatin, gemcitabine/cisplatin, vinorelbine/ cisplatin) while 19 patients (11.2%) received non-platinumbased chemotherapy (ifosfamide/doxorubicin, or highdose methotrexate). Elderly patients older than 70 years old and/or patients with a bad PS who could not tolerate chemotherapy were offered best supportive care (BSC) Similarly, Ceresoli et al. (28) showed that overall, 198 patients (82%) underwent an active treatment, whereas 43 (18%) received best supportive care (BSC) only. Active treatment was given in 18 patients who consisted of multimodality therapy (including any kind of surgery, chemotherapy and in some cases radiotherapy) and chemotherapy as single modality therapy was given in 180 patients. In patients more than75 years (n = 122), 3 cases were treated with multimodality therapy, 86 with chemotherapy, and 33 received BSC. The respective numbers for patients more than 80 years (n = 48) were 0, 30 and 18 cases.
However Billé et al. (25) study showed that chemotherapy was given in all study patients (177 patients) and 90% of patients received pemetrexed.
After receiving first line chemotherapy in the present study we found that only 2.5% of patients showed complete remission, 45.7%showed PD, 30.9% showed PR and 19.8% showed SD among 14 patients who had second line chemotherapy; 50% patients showed progressive disease and 28.6% had PR and,21.4% had SD.and after receiving 3 rd line chemotherapy 60% of patients showed SD, while 20% showed PR and PD. This is partially in agreement with results of Ceresoli et al. (28) , they showed that first-line chemotherapy (as single treatment or as a part of multimodality therapy) was mainly pemetrexed based, most patients treated with the combination of pemetrexed and carboplatin. Overall, 178 patients (74% of the study population) received a pemetrexed-based regimen. Response was not assessed or not reported in 23 cases; a complete or partial response was achieved in 1 and 45 patients, respectively, for a response rate of 23%; 75 patients had stable disease (38%) and 54 patients progressed; therefore, A second-line treatment was administered to 87 patients About a quarter of patients were rechallenged with pemetrexed; the remaining received a gemcitabine or vinorelbine based regimen. Overall, response to second-line therapy was observed in 4 cases (28.6%) in form of PR, with 3 patients having stable disease.
This coincides with results of Karabulut et al. (24) who showed that the number of patients who responded to treatment was 29 (54.7%). Complete response was achieved in two patients (3.8%) and partial response in 12 patients (22.6%). 34 patients (64.2%) had stable disease. Posttreatment progression was detected in 5 patients as locoregional relapse (9.4%).
Also, this is partially in agreement with results of Adel et al. (4) who showed that 152 of the patients who received chemotherapy (89.9%) were assessable for response (after at least two courses of chemotherapy). Four patients (2.6%) attained complete response (CR), 33 patients (21.7%) had partial response (PR) and 68 patients (44.7%) had stable disease (SD), while, 47 patients (30.9%) progressed PD. For analysis in this study, patients were categorized into two groups according to response. Responders comprised CR+PR+SD (105 patients) while, non-responders comprised PD (47 patients). Sixty-nine patients received 2 lines of chemotherapy. The range of
